

Certificate of Analysis

pGL4.45[*luc2P*/ISRE/Hygro] Vector:

Part No. Size
E414A 20µg

Description: The pGL4.45[*luc2P*/ISRE/Hygro] Vector^(a-c) Vector contains five copies of an interferon-stimulated response element (ISRE) that drives transcription of the luciferase reporter gene *luc2P* (*Photinus pyralis*). *luc2P* is a synthetically derived luciferase sequence with humanized codon optimization that is designed for high expression and reduced anomalous transcription. The *luc2P* gene contains hPEST, a protein destabilization sequence, which allows *luc2P* protein levels to respond more quickly than those of *luc2* to induction of transcription. The vector backbone contains an ampicillin resistance gene to allow selection in *E. coli* and a gene for hygromycin resistance to allow selection of stably transfected mammalian cell lines.

Concentration: 1µg/µl.

GenBank® Accession Number: JQ858514.

Storage Buffer: The pGL4.45[*luc2P*/ISRE/Hygro] Vector is supplied in 10mM Tris-HCl (pH 7.4), 1mM EDTA.

Storage Conditions: See the product information label for storage temperature recommendations. Avoid multiple freeze-thaw cycles and exposure to frequent temperature changes. See the expiration date on the product information label.

Usage Notes:

This plasmid may show instability when propagated in certain strains of *E. coli*, losing one or more of the ISRE repeats upstream of the minimal promoter. We recommend propagating this strain in STBL2 cells (Life Technologies Cat. # 10268-019) at 30°C.

Concentration gradients may form in frozen products and should be dispersed upon thawing. Mix well prior to use.

Quality Control Assays

Nuclease Assay: Following incubation of 1µg of the vector in Restriction Enzyme Buffer at 37°C for 16–24 hours, no evidence of nuclease activity is detected by agarose gel electrophoresis.

Physical Purity: $A_{260}/A_{280} \geq 1.80$, $A_{260}/A_{250} \geq 1.05$.

Sequence: The pGL4.45[*luc2P*/ISRE/Hygro] Vector has been completely sequenced and has 100% identity with the published sequence, available at: www.promega.com/vectors/

Signed by:

R. Wheeler, Quality Assurance

(a) BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE LABEL LICENSE. If the researcher is not willing to accept the terms of this label license, and the product is unused, Promega will accept return of the unused product and provide the researcher with a full refund.

Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for money or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene except that researchers may: (1) create fused gene sequences provided that the coding sequence of the resulting luciferase gene has no more than four deoxynucleotides missing at the affected terminus compared to the intact luciferase gene sequence, and (2) insert and remove nucleic acid sequences in splicing research predicated on the inactivation or reconstitution of the luminescence of the encoded luciferase. No other use or transfer of this product or derivatives is authorized without the prior express written consent of Promega. In addition, researchers must either: (1) use luminescent assay reagents purchased from Promega for all determinations of luminescence activity of this product and its derivatives; or (2) contact Promega to obtain a license for use of the product and its derivatives. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA. This label license relates to Promega patents and/or patent applications on improvements to the luciferase gene.

(b) U.S. Pat. No. 7,728,118.

(c) U.S. Pat. No. 8,008,006 and European Pat. No. 1341808.

Part# 9PIE414
Revised 4/18



AF9PIE414 0418E414



Promega

Promega Corporation

2800 Woods Hollow Road	
Madison, WI 53711-5399 USA	
Telephone	608-274-4330
Toll Free	800-356-9526
Fax	608-277-2516
Internet	www.promega.com

PRODUCT USE LIMITATIONS, WARRANTY, DISCLAIMER

Promega manufactures products for a number of intended uses. Please refer to the product label for the intended use statements for specific products. Promega products contain chemicals which may be harmful if misused. Due care should be exercised with all Promega products to prevent direct human contact.

Each Promega product is shipped with documentation stating specifications and other technical information. Promega products are warranted to meet or exceed the stated specifications. Promega's sole obligation and the customer's sole remedy is limited to replacement of products free of charge in the event products fail to perform as warranted. Promega makes no other warranty of any kind whatsoever, and SPECIFICALLY DISCLAIMS AND EXCLUDES ALL OTHER WARRANTIES OF ANY KIND OR NATURE WHATSOEVER, DIRECTLY OR INDIRECTLY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE SUITABILITY, PRODUCTIVITY, DURABILITY, FITNESS FOR A PARTICULAR PURPOSE OR USE, MERCHANTABILITY, CONDITION, OR ANY OTHER MATTER WITH RESPECT TO PROMEGA PRODUCTS. In no event shall Promega be liable for claims for any other damages, whether direct, incidental, foreseeable, consequential, or special (including but not limited to loss of use, revenue or profit), whether based upon warranty, contract, tort (including negligence) or strict liability arising in connection with the sale or the failure of Promega products to perform in accordance with the stated specifications.

© 2012, 2016, 2018 Promega Corporation. All Rights Reserved.

GloMax is a registered trademark of Promega Corporation. ONE-Glo is a trademark of Promega Corporation.

FuGENE is a registered trademark of Fugent, L.L.C., USA. GenBank is a registered trademark of the U.S. Department of Health and Human Services. Opti-MEM is a registered trademark of Life Technologies, Inc.

Products may be covered by pending or issued patents or may have certain limitations. Please visit our Web site for more information.


All specifications are subject to change without prior notice.

Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the most up-to-date information on Promega products.

Part# 9PIE414
Printed in USA. Revised 4/18.

pGL4.45[*Luc2P*/ISRE/Hygro] Vector Features List and Map:

ISRE response element	285–359
Minimal promoter	405–435
<i>Luc2P</i> reporter gene	468–2243
SV40 late poly(A) signal	2283–2504
SV40 early enhancer/promoter	2552–2970
Synthetic hygromycin (Hyg ^r) coding region	2995–4032
<i>ColE1</i> -derived plasmid replication origin	4428
Synthetic β-lactamase (Amp ^r) coding region	5219–6079
Synthetic poly(A) signal sequence	4056–4104
Synthetic poly(A) signal/transcriptional pause site	105–258
Reporter Vector primer 3 (RVprimer3) binding region	207–226
Reporter Vector primer 4 (RVprimer4) binding region	4171–4190



Sequence information for the pGL4 Vectors is available online at: www.promega.com/vectors/

Example Protocol

In this example protocol, the pGL4.45[*Luc2P*/ISRE/Hygro] Vector is used to measure activation of the ISRE in U2OS cells upon treatment with interferon-alpha. In designing such experiments, it is important that the chosen cell type can be transfected efficiently and that it expresses the proper components of the signaling pathway of interest in order to generate the biological response. Protocol optimization may be required for your particular cell type and assay conditions.

Materials to be Supplied by User

- Complete medium (McCoy's 5A [Life Technologies Cat.# 16600] + 10% FBS [HyClone Cat.# SH30070.03])
- 0.05% Trypsin-EDTA (Life Technologies Cat.# 25300)
- Dulbecco's PBS (DPBS; Life Technologies Cat.# 14190)
- Opti-MEM® 1 (Life Technologies Cat.# 31985)
- FuGENE® HD Transfection Reagent (Cat.# E2311)
- Interferon-alpha (IFN-alpha; EMD Cat.# 407294)
- ONE-Glo® Luciferase Assay System (Cat.# E6120)
- U2OS cells

Day 1: Reverse Transfection

Preparation of Cells

1. Grow U2OS cells in complete medium (McCoy's 5A + 10% FBS). Wash with DPBS and treat with one volume of 0.05% trypsin-EDTA. Resuspend the cells in four volumes of complete medium.
2. Quantify cells and dilute in complete medium to 2×10^5 cells/ml.

Preparation of Lipid:DNA Mixture

1. Dilute pGL4.45[*Luc2P*/ISRE/Hygro] DNA to 10ng total DNA/μl in Opti-MEM® 1.
2. Add FuGENE® HD to a 3:1 lipid:DNA ratio. Mix by pipetting. Incubate at room temperature for 30 minutes.
3. Dilute lipid:DNA mixture 20-fold with 2×10^5 cells/ml cell suspension. Mix by inversion.
4. Plate 100μl per well into a solid, white 96-well plate (Corning Cat.# 3917).
5. Incubate for 18 hours in a 37°C, 5% CO₂ incubator.

Day 2: Cell Treatment

1. Serially dilute IFN-alpha into complete medium to give 10X stock solutions.
2. Add 10μl of the 10X dilutions of IFN-alpha to each well.
3. Incubate for 16 hours in a 37°C, 5% CO₂ incubator.

Day 3: Luminescence Measurement

1. Remove plates from the 37°C, 5% CO₂ incubator. Allow plates to cool to room temperature for approximately 15 minutes.
2. Add 100μl ONE-Glo® Luciferase Assay System detection reagent to each well and measure luminescence following the recommended protocol (Refer to the ONE-Glo™ Luciferase Assay System Technical Manual, #TM292 for details).




Figure 1. Representative data for pGL4.45[*Luc2P*/ISRE/Hygro] in U2OS cells upon stimulation with IFN-alpha. U2OS cells were transiently transfected with pGL4.45[*Luc2P*/ISRE/Hygro] and assayed in 96-well format after 16 hours stimulation with IFN-alpha as indicated in the protocol. Firefly luciferase luminescence normalized to untreated cells is shown, with error bars indicating the S.E.M. for three replicates. Luminescence was detected after addition of ONE-Glo® reagent, using a GloMax®-Multi+ instrument with a 0.5 second integration time.